Physician profile
Mallory E Reed
NPI 1982947883
$7,341.73
in general payments reported to CMS, 2019-2025
34 companies · $1,758 in 2025
The $1,758 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,056 · 2022: $1,129 · 2023: $1,561 · 2024: $1,837 · 2025: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,155.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,281.46 | 2021-2025 | |
| Novo Nordisk INC | $823.01 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $818.59 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $504.42 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.93 | 2021-2025 | Jardiance, Stiolto Respimat |
| Lundbeck LLC | $410.86 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $344.57 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $331.76 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $316.85 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $247.28 | 2021-2025 | Trelegy Ellipta |
| Dexcom, INC. | $229.28 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.57 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $191.98 | 2021-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.16 | 2022-2025 | Caplyta |
| Amgen INC. | $135.54 | 2021-2024 | Repatha, Otezla, Evenity |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $126.78 | 2021-2024 | Xarelto, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $92.33 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $78.40 | 2023-2025 | Ingrezza |
| Sanofi-Aventis U.S. LLC | $74.90 | 2021 | |
| Amarin Pharma, INC. | $72.08 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $65.11 | 2022-2024 | |
| Abbott Laboratories | $60.06 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $56.43 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $42.39 | 2023-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $33.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $33.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.05 | 2023 | Quviviq |
| Alkermes, INC. | $21.88 | 2025 | Aristada, Lybalvi |
| Sanofi Pasteur INC. | $21.84 | 2023 | |
| Horizon Therapeutics Plc | $21.18 | 2022 | |
| Teleflex LLC | $21.01 | 2025 | Guideliner |
| Teva Pharmaceuticals USA, INC. | $17.23 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.08 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.